Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728531 · ClinicalTrials.gov registry record · Phase 1
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02728531 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 18 participants.
The verdict
NCT02728531, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Given the established role of high dose cytarabine (HiDAC) combined with rituximab, along with recent data showing the encouraging efficacy of bendamustine, the investigators seek to integrate the synergistic effects of these medicines in alternating cycles as induction therapy prior to autologous stem cell transplant (ASCT). Based on prior experience with bendamustine and rituximab (BR) based induction therapy, the investigators seek to evaluate the efficacy and safety of stem cell mobilization in this pilot study
Interventions
- DRUG Rituximab
- DRUG Cytarabine
- PROCEDURE Leukapheresis
- DRUG Bendamustine
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-04-18 |
| Est. Completion | 2023-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02728531
The ClinicalTrials.gov registry entry for NCT02728531 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT02728531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02728531 about?
NCT02728531 is a clinical study titled "Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma". Given the established role of high dose cytarabine (HiDAC) combined with rituximab, along with recent data showing the encouraging efficacy of bendamustine, the investigators seek to integrate the synergistic effects of these medicines in alternating cycles as induction therapy prior to autologous s...
What is the current status of trial NCT02728531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-04-18. Estimated completion is 2023-08-16.
What interventions are being tested in trial NCT02728531?
The interventions under investigation include: Rituximab (DRUG), Cytarabine (DRUG), Leukapheresis (PROCEDURE), Bendamustine (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT02728531?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.